ClinicalTrials.gg

Program

dapirolizumab pegol

Also written as “Dapirolizumab pegol (DZP)”, “DZP” and “CDP7657”.

Its studies are mostly in Lupus Erythematosus, Systemic, led by 2 companies.

Furthest: phase 3, since Feb 27, 20208 company-led studies, 3 open or runningNext primary completion: May 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCB73 open or runningphase 3since Feb 27, 2020Mar 12, 2010May 31, 2028phase 3 · NCT06617325
Biogen10 open or runningphase 1since Sep 25, 2020Sep 25, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 12, 2010First study: phase 1 study in Immune System DiseasesNew to UCBUCB · NCT01093911 · 44 enrolled · Belgium, Bulgaria, Germany
  2. Jan 2, 2013Phase 1 study in Immune System DiseasesUCB · NCT01764594 · 24 enrolled · Belgium, Bulgaria, Germany and more
  3. Jun 14, 2016Phase 2 study in Lupus Erythematosus, SystemicUCB · NCT02804763 · 182 enrolled · United States, Bulgaria, Chile and more
  4. Feb 27, 2020Phase 3 study in Lupus Erythematosus, SystemicUCB · NCT04294667 · 321 enrolled · United States, Argentina, Australia and more
  5. Sep 25, 2020Biogen's first study: phase 1 study in Healthy VolunteersNew to BiogenBiogen · NCT04571424 · 33 enrolled · United States
  6. Jul 14, 2021Phase 3 study in Lupus Erythematosus, SystemicUCB · NCT04976322 · 760 planned · United States, Argentina, Belgium and more
  7. Sep 24, 2024Phase 3 study in Lupus Erythematosus, SystemicUCB · NCT06617325 · 450 planned · United States, Argentina, Belgium and more
  8. Nov 6, 2026Phase 1 study in Lupus Erythematosus, SystemicUCB · NCT07934472 · 25 planned

Ahead

  1. May 31, 2028Primary completion: phase 3 study in Lupus Erythematosus, SystemicUCB · NCT06617325
  2. Dec 31, 2028Primary completion: phase 1 study in Lupus Erythematosus, SystemicUCB · NCT07934472
  3. Aug 7, 2030Primary completion: phase 3 study in Lupus Erythematosus, SystemicUCB · NCT04976322

TargetBeta

CD40LG →read by rule
“CD40 ligand inhibitor”ChEMBL 37, by rule

Other programs on CD40LG

ProgramCompanyFurthest phaseStudies
frexalimabSanofiphase 311
dazodalibepruleAmgenphase 39
tegoprubartruleeledon-pharmaceuticalsphase 38
ravagalimabruleAbbViephase 24
OPT101ruleop-t-llcphase 24
TNX-1500ruleTonix Pharmaceuticalsphase 11

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07934472Lupus Erythematosus, Systemic1Not yet recruitingUCBDec 31, 202825
NCT06617325Lupus Erythematosus, Systemic · United States, Argentina, Belgium and more3RecruitingUCBMay 31, 2028450
NCT04976322Lupus Erythematosus, Systemic · United States, Argentina, Belgium and more3By invitationUCBAug 7, 2030760
NCT04571424Healthy Volunteers · United States1CompletedBiogenApr 8, 202133
NCT04294667Lupus Erythematosus, Systemic · United States, Argentina, Australia and more3CompletedUCBMay 22, 2024321
NCT02804763Lupus Erythematosus, Systemic · United States, Bulgaria, Chile and more2CompletedUCBMay 31, 2018182
NCT01764594Immune System Diseases · Belgium, Bulgaria, Germany and more1CompletedUCBAug 201424
NCT01093911Immune System Diseases · Belgium, Bulgaria, Germany1CompletedUCBDec 201244

How it is read

Names in the registry

  • “Dapirolizumab pegol (DZP)”, 2 entries
  • “DZP”, 2 entries
  • “CDP7657”, 2 entries
  • “Dapirolizumab pegol”, 1 entry
  • “BIIB133 (Dapirolizumab pegol)”, 1 entry

Codes read as this program: CDP7657.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.